SCHEMBL20598528

SCHEMBL20598528

O=C(Nc1ccc(CC(=O)N2CCOCC2)cc1N1CCCCC1)c1ccc(Br)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 4/20 0.61
▸ ALDH1A1 P00352 5/20 0.60
▸ MAPK10 P53779 3/20 0.60
▸ TSHR P16473 3/20 0.60
▸ HPGD P15428 2/20 0.60
▸ HTT P42858 4/20 0.59
▸ GAA P10253 2/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ NPC1 O15118 6/20 0.56
▸ RAB9A P51151 6/20 0.56
▸ MAPT P10636 3/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ TP53 P04637 2/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ LMNA P02545 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ MAPK1 P28482 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20598696 0.92 NPC1 (0.64) CSF1RALDH1A1MAPK10TSHRHPGD
SCHEMBL20598407 0.86 NPC1 (0.63) CSF1RALDH1A1MAPK10TSHRHPGD
SCHEMBL20598198 0.85 CSF1R (0.62) CSF1RALDH1A1MAPK10TSHRHPGD
SCHEMBL20598626 0.84 CSF1R (0.61) CSF1RALDH1A1MAPK10TSHRHPGD
SCHEMBL20598140 0.84 ALDH1A1 (0.67) CSF1RALDH1A1MAPK10TSHRHPGD
SCHEMBL20598360 0.82 PIM1 (0.46) CSF1RALDH1A1MAPK10TSHRHPGD
SCHEMBL20598602 0.82 PIM1 (0.44) CSF1RSMN1; SMN2KMT2AMEN1
SCHEMBL30501479 0.82 PIM1 (0.46) CSF1RALDH1A1MAPK10TSHRHPGD
SCHEMBL20598498 0.79 NPC1 (0.65) CSF1RALDH1A1MAPK10TSHRHPGD
SCHEMBL20598518 0.78 NPC1 (0.66) CSF1RALDH1A1MAPK10TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111032642-B Kinase inhibitors and methods of making and using the same 里格尔药品股份有限公司 2023-07-18 — — CN disclosed
US-20210309655-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING RIGEL PHARMACEUTICALS, INC. (US) 2021-10-07 — — US disclosed
US-20210309655-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING RIGEL PHARMACEUTICALS, INC. (US) 2021-10-07 — — US disclosed
US-11059814-B2 Kinase inhibitors and methods for making and using RIGEL PHARMACEUTICALS, INC. (US) 2021-07-13 — — US disclosed
US-11059814-B2 Kinase inhibitors and methods for making and using RIGEL PHARMACEUTICALS, INC. (US) 2021-07-13 — — US disclosed
US-20200181135-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING RIGEL PHARMACEUTICALS, INC. (US) 2020-06-11 — — US disclosed
US-20200181135-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING RIGEL PHARMACEUTICALS, INC. (US) 2020-06-11 — — US disclosed
CN-111032642-A Kinase inhibitors and methods of making and using 里格尔药品股份有限公司 2020-04-17 — — CN disclosed
US-10590121-B2 Kinase inhibitors and methods for making and using RIGEL PHARMACEUTICALS, INC. (US) 2020-03-17 — — US disclosed
US-10590121-B2 Kinase inhibitors and methods for making and using RIGEL PHARMACEUTICALS, INC. (US) 2020-03-17 — — US disclosed
WO-2019006126-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING RIGEL PHARMACEUTICALS, INC. (US) 2019-01-03 — — WO disclosed
US-20190002455-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING RIGEL PHARMACEUTICALS, INC. (US) 2019-01-03 — — US disclosed
US-20190002455-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING RIGEL PHARMACEUTICALS, INC. (US) 2019-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002455-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING IRAK1, IRAK2, IRAK3 CSF1R 693/4885ALDH1A1 2414/4885MAPK10 295/4885
US-20210309655-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING IRAK1, IRAK2, IRAK3 CSF1R 693/4885ALDH1A1 2414/4885MAPK10 295/4885
US-10590121-B2 Kinase inhibitors and methods for making and using IRAK1, IRAK2, IRAK3 CSF1R 419/4885ALDH1A1 1343/4885MAPK10 185/4885
US-20200181135-A1 KINASE INHIBITORS AND METHODS FOR MAKING AND USING IRAK1, IRAK2, IRAK3 CSF1R 693/4885ALDH1A1 2414/4885MAPK10 295/4885
US-11059814-B2 Kinase inhibitors and methods for making and using IRAK1, IRAK2, IRAK3 CSF1R 569/4885ALDH1A1 1328/4885MAPK10 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback